Boehringer Ingelheim Initiates Phase III Clinical Trial With Novel Oral Agent...
Boehringer Ingelheim announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced...
View ArticleAfatinib (BIBW 2992) Improves Progression Free Survival In Phase III Study In...
Boehringer Ingelheim announced results from two clinical trials of its investigational cancer compound afatinib (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress...
View ArticleAssociate Director Pharmacology – Oncology Drug Discovery Job at Boehringer...
Details zum Job Group Leader / Associate Director (m/f) Pharmacology / Oncology Drug Discovery in Wien: Group Leader / Associate Director (m/f) Pharmacology / Oncology Drug Discovery Boehringer...
View ArticleAfatinib (BIBW 2992) Triples Progression Free Survival In Phase III Study In...
Boehringer Ingelheim announced promising results from two clinical trials of its investigational cancer compound afatinib (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO)...
View ArticleBoehringer Ingelheim Broadens its Breast Cancer Trial Programme for Afatinib
Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib* in patients with metastatic breast cancer, who have an overexpression of the...
View Article
More Pages to Explore .....